The Effect of Ketamine on Attentiveness
NCT01165294 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Cerebral activation of ketamine as determined by functional MRI
Measured over 25 and 40 minutes after end of bolus injection of ketamine/placebo
Cerebral activation of ketamine as determined by electroencephalogram (EEG) during an oddball-task
Measured over 25 and 40 minutes after end of bolus injection of ketamine/placebo
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT01165294 on ClinicalTrials.gov →
Last updated in the registry 2010-08-06. Registry records change; this page reflects the data build of 2026-08-25.
Related